Moderna said on Monday its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot.
A worst-case scenario would be a surge of one or more strains that evade our immune protections just as a predicted fall and winter surge hits the United States.